Main Menu

ART DECO

A randomised, multicentre accelerated radiotherapy study of dose escalated intensity-modulated radiotherapy versus standard dose intensity-modulated radiotherapy in patients receiving treatment for locally advanced laryngeal and hypopharyngeal cancers.

Disease site: Head and neck cancer

Treatment modality: Radiotherapy

Status: In follow up

Trial details

ART DECO is a phase III, multicentre, randomised controlled trial to determine the potential of dose escalated intensity-modulated radiotherapy (IMRT) to improve locoregional failure free rate and laryngeal preservation in patients with locally advanced laryngeal and hypopharyngeal cancers, without increasing the incidence of severe acute and late toxicities to unacceptable levels.

ART DECO recruited 276 patients and closed to recruitment in October 2015. Participants are now being followed up for at least a further 5 years. In ART DECO, patients received either dose escalated IMRT or standard dose IMRT. Dose escalated IMRT delivered 67.2 Gy in 28 fractions to the involved site and nodal groups, and 56 Gy in 28 fractions to nodal areas at risk of harbouring microscopic disease; standard dose IMRT was lower.

Further information

Chief Investigator: Professor Christopher Nutting, The Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Dr Emma Hall

Trial management contact: [email protected]

ISRCTN: 01483375

Sponsor: The Royal Marsden NHS Foundation Trust

Funding: Cancer Research UK (CRUK/10/018)

Further information including recruitment progress is available from the UK Clinical Trials Gateway.

A plain English summary is available from Cancer Research UK.

Publications and presentations

There have been no presentations or publications to date

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.